<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936166</url>
  </required_header>
  <id_info>
    <org_study_id>CRN01941-01</org_study_id>
    <nct_id>NCT03936166</nct_id>
  </id_info>
  <brief_title>A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CRN01941 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crinetics Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crinetics Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, double-blind, randomized, placebo-controlled, single-dose and
      multiple-dose study of CRN01941 in up to 119 healthy male and female subjects. This
      single-center study will be conducted in 3 parts: a single-ascending dose phase (up to 8
      cohorts, 8 subjects/cohort), a multiple-ascending dose phase (up to 5 cohorts, 9
      subjects/cohort), and single dose phase in elderly subjects (1 cohort, 10 subjects).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single and multiple-dose cohorts are placebo-controlled.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment emergent adverse events by severity</measure>
    <time_frame>Part 1 - up to Day 8; Part 2 - up to Day 20; Part 3 - up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with serious adverse events (SAEs)</measure>
    <time_frame>Part 1 - up to Day 8; Part 2 - up to Day 20; Part 3 - up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs</measure>
    <time_frame>Part 1 - up to Day 8; Part 2 - up to Day 20; Part 3 - up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with ECG abnormalities</measure>
    <time_frame>Part 1 - up to Day 8; Part 2 - up to Day 20; Part 3 - up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinical laboratory abnormalities</measure>
    <time_frame>Part 1 - up to Day 8; Part 2 - up to Day 20; Part 3 - up to Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC)</measure>
    <time_frame>Part 1 - up to Day 8; Part 2 - up to Day 20; Part 3 - up to Day 8</time_frame>
    <description>Assessment of the plasma area under the curve of CRN01941</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Cmax)</measure>
    <time_frame>Part 1 - up to Day 8; Part 2 - up to Day 20; Part 3 - up to Day 8</time_frame>
    <description>Assessment of the maximum observed plasma concentration of CRN01941</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Tmax)</measure>
    <time_frame>Part 1 - up to Day 8; Part 2 - up to Day 20; Part 3 - up to Day 8</time_frame>
    <description>Assessment of the time to reach Cmax for CRN01941</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (T1/2)</measure>
    <time_frame>Part 1 - up to Day 8; Part 2 - up to Day 20; Part 3 - up to Day 8</time_frame>
    <description>Assessment of the elimination half-life of CRN01941</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">119</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Cohort (Part 3)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRN01941 Oral Solution</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>Elderly Cohort (Part 3)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (Part 2)</arm_group_label>
    <arm_group_label>Single Ascending Dose (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRN01941 Oral Capsule</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>Elderly Cohort (Part 3)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (Part 2)</arm_group_label>
    <arm_group_label>Single Ascending Dose (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Solution</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Elderly Cohort (Part 3)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (Part 2)</arm_group_label>
    <arm_group_label>Single Ascending Dose (Part 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Elderly Cohort (Part 3)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (Part 2)</arm_group_label>
    <arm_group_label>Single Ascending Dose (Part 1)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects 18 to 55 years of age, inclusive, at time of screening (Parts
             1 and 2 only).

          2. Males and females subjects 65 to 85 years of age at screening (Part 3 only).

          3. Females must be non-pregnant and non-lactating, postmenopausal by history and
             confirmed by follicle stimulating hormone (FSH) &gt;30 U/L at Screening, or surgically
             sterile.

          4. Male subjects must be surgically sterile or agree to use highly effective form of
             contraception when sexually active with a female partner of child bearing potential.

          5. Body mass index (BMI) of 18 to 32 kg/m2, inclusive at Screening.

          6. Willing to provide signed informed consent.

        Exclusion Criteria:

          1. Any uncontrolled or active major systemic disease which makes study participation
             unsafe or could interfere with evaluation of the endpoints of the study.

          2. History or presence of malignancy within the past 5 years, not including treated basal
             cell carcinomas and in situ cervical neoplasia.

          3. Use of any investigational drug within the past 60 days.

          4. Have a medically significant abnormality observed during screening or admission.

          5. Use of any prior medication without approval of the investigator within 14 days prior
             to admission.

          6. Subjects with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
             infections. Subjects with previous hepatitis C infection that is now cured may be
             eligible.

          7. History of or current alcohol or substance abuse in the past 12 months

          8. Any condition that in the opinion of the investigator would jeopardize the subject's
             appropriate participation in this Phase 1 study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Crinetics Clinical Trials</last_name>
    <phone>833-827-9741</phone>
    <email>clinicaltrials@crinetics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>May 21, 2019</last_update_submitted>
  <last_update_submitted_qc>May 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

